Wave Life Sciences Ltd., of Cambridge, Mass., said preclinical data of WVE-3972-01, a stereopure antisense oligonucleotide designed to target the pathogenic allele of the C90RF72 gene to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), showed it demonstrated substantial reduction in disease-associated biomarkers and superior potency to stereorandom oligonucleotides.